The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines, with Novartis Pharma’s radioligand therapy Pluvicto (lutetium vipivotide tetraxetan (177Lu)) forecast to achieve the highest peak sales among them. The…
To read the full story
Related Article
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Izervay, Vorzzz, Dormicum Syrup Now Available in Japan
November 28, 2025
- Otsuka’s Hypercholesterolemia Med Nexletol Hits Japan Shelves
November 25, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
- Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
- Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster
September 22, 2025
REGULATORY
- Chuikyo OKs Medical Materials Reform Outline, Price Hikes Possible for Loss-Making Devices
January 5, 2026
- MHLW FY2026 Budget Hits Record 35 Trillion Yen, Drug Discovery Support Set at 7.1 Billion Yen
January 5, 2026
- Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
- Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
- Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…